610309-89-2COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O.O=P(O)(O)O.O=P(O)(O)OLHNYXTULDSJZRB-UHFFFAOYSA-NCarvedilol Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity. The S enantiomer of carvedilol nonselectively binds to and blocks beta-adrenergic receptors, thereby exerting negative inotropic and chronotropic effects, and leading to a reduction in cardiac output. In addition, both enantiomers of carvedilol bind to and block alpha 1-adrenergic receptors, thereby causing vasodilation and reducing peripheral vascular resistance.
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Warning
H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]
P261, P272, P273, P280, P302+P352, P321, P333+P317, P362+P364, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
CARVEDILOL PHOSPHATE
Adrenergic beta2-Antagonists [MoA]; Adrenergic alpha-Antagonists [MoA]; alpha-Adrenergic Blocker [EPC]; Adrenergic beta1-Antagonists [MoA]; beta-Adrenergic Blocker [EPC]
UsesTreatment of congestive heart failure, left ventricular dysfunction following myocardial infarction, and management of hypertension.
610309-89-2DTXSID60976535CHEMBL1201167